Business Context and Reporting Period
Tvardi Therapeutics, Inc. (TVRD) filed a Form 8-K on August 14, 2026, to announce financial results and business highlights for the fiscal quarter ended June 30, 2026. The company is incorporated in Delaware and trades on The Nasdaq Stock Market LLC. The filing incorporates a press release (Exhibit 99.1) by reference but explicitly states that the information is furnished under Item 2.02 and is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Key Financial Metrics
The provided filing text serves as a cover document and does not contain specific numerical data. Consequently, the following metrics are not available in this source text:
- Revenue
- Profit or Net Loss
- Cash Flow
- Operating Margins
- Debt Levels
- Liquidity Position
Investors must refer to the attached Exhibit 99.1 (Press Release) for detailed financial figures.
Material Changes
The filing text does not provide specific data regarding material changes in financial performance or operational metrics compared to the prior comparable period. The document only confirms the issuance of a press release containing these results.
Guidance, Outlook, and Risks
While the filing references a press release containing "business highlights," the text of the 8-K itself does not include specific guidance, management commentary, risk factors, contingencies, or unusual items. The document notes that the information is not subject to the liabilities of Section 18 of the Exchange Act or Sections 11 and 12(a)(2) of the Securities Act.
Investor Verification Checklist
- Verify the specific revenue, net loss, and cash burn figures in the attached Exhibit 99.1 press release.
- Confirm the company's cash runway and liquidity position as of June 30, 2026.
- Review the "business highlights" mentioned in the press release for updates on clinical trials or regulatory milestones.
- Check for any forward-looking statements or guidance provided in the press release that are not included in this 8-K summary.